Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Virus Diseases 1Liver Cirrhosis 1Hepatitis, Viral, Human 1Hepatitis C 1Carcinoma, Hepatocellular 1

Interventions

human papillomavirus vaccine, L1 type 16, 18 3Oncolytic Virotherapy 2Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 2Bevacizumab 2valrubicin 1thymoglobulin 1ledipasvir, sofosbuvir drug combination 1hepatitis C immune globulin, human 1halofantrine 1VP-102 1Therapies, Investigational 1Tenofovir 1Rituximab 1Radiotherapy, Intensity-Modulated 1Papillomavirus Vaccines 1Nimorazole 1Mitomycin 1Lamivudine 1Kidney Transplantation 1Ipilimumab 1Interferons 1Influenza Vaccines 1Immunoglobulin G 1Imiquimod 1Gemcitabine 1Gels 1Fluorescent Antibody Technique 1Drug Therapy 1Cyclophosphamide 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Virus Diseases × hepatitis C immune globulin, human × Clear all
NCT01804829 2017-03-15

Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.

Biotest Pharmaceuticals Corporation

Phase 3 Completed
80 enrolled
Gastrointestinal

Hepatitis, Viral, Human, Hepatitis C, Carcinoma, Hepatocellular, Liver Cirrhosis, Virus Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡